Have any questions? 706-721-6582 or cts@augusta.edu
- Brain Vascular Malformation Consortium (BVMC3) Project 3: Cerebral Hemorrhage Risk in Hereditary Hemorrhagic Telangiectasia
Clinical Trial
Brain Vascular Malformation Consortium (BVMC3) Project 3: Cerebral Hemorrhage Risk in Hereditary Hemorrhagic Telangiectasia
The purpose of this study is to learn more about brain AVMs (BAVMs) and bleeding in HHT. We plan to study risk factors for rupture of BAVMs. We also will study risk factors for other bleeding and features of HHT disease, including primarily genetics and imaging characteristics of the BAVMs. We hope that knowledge about risk factors will help improve the care and management of HHT patients.
Eligibility Criteria
- INCLUSION: Patients with HHT (1:3 ratio of recruits with and without BAVMs) Inclusion Criteria: A). Definite clinical HHT diagnosis (at least 3 Curacao criteria) or genetic diagnosis of HHT OR B). Definite clinical HHT diagnosis (at least 3 Curacao criteria) or genetic diagnosis of HHt. Presence of BAVM able to provide informed consent. EXCLUSION: None
RESEARCH. INNOVATION. DISCOVERY.